HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
VTGN
VistaGen Therapeutics, Inc.
There isn't enough reported data to score VTGN yet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
VTGN Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Weak | |
| Unavailable |
VTGN's revenue is currently strong, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
VTGN PE Valuation
VTGN has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
VTGN Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses shrinking | |
| Strong growth | |
| -- | |
| Limited | |
| High |
Analysts expect VTGN's losses to shrink, with revenue growing.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
VTGN Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$1.66 | +$0.13 |
| Q1 2026 | -$1.83 | -$0.16 |
| Q4 2023 | -$3.53 | +$5.77 |
| Q3 2023 | -$4.81 | +$4.49 |
| Q2 2023 | -$6.55 | +$2.45 |
| Q1 2023 | -$8.61 | -$1.41 |
| Q4 2022 | -$9.30 | +$1.50 |
| Q3 2022 | -$9.30 | +$2.10 |
VTGN has the edge over HIMS on earnings, with more consistent year-over-year improvement.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over VTGN on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over VTGN on profitability, with a higher operating margin.
VTGN Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $1.5M | +505% |
| Q4 2025 | $303K | +29% |
| Q3 2025 | $258K | +41% |
| Q2 2025 | $244K | +190% |
| Q4 2024 | $234K | -43% |
| Q3 2024 | $183K | -34% |
| Q1 2024 | $197.3K | +12% |
| Q1 2023 | $176K | +351% |
VTGN's revenue has grown year over year for five quarters in a row: $1M last quarter, up 505% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -904% | +5573 points |
| Q1 2026 | -3595% | N/A |
| Q4 2025 | -6451% | +11 points |
| Q3 2025 | -7772% | +1.8 points |
| Q2 2025 | -6477% | +7965 points |
| Q4 2024 | -6462% | -4545 points |
| Q3 2024 | -7774% | -5333 points |
| Q2 2024 | -14442% | N/A |
VTGN's operating margin was −904% last quarter, up 5573 points from the same quarter a year ago, near the top of its range since 2020.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over VTGN on cash generation, producing positive trailing cash flow while its opponent burns cash.
VTGN Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$14.7M | +$4.1M |
| Q1 2026 | -$16.2M | -$6.1M |
| Q4 2025 | -$17.6M | -$7.4M |
| Q3 2025 | -$13.8M | -$2.9M |
| Q2 2025 | -$18.8M | -$8M |
| Q4 2024 | -$10.3M | -$5.7M |
| Q3 2024 | -$10.9M | -$4.7M |
| Q2 2024 | -$10.9M | -$3M |
VTGN has burned cash in almost every quarter: −$62M over the past year, against −$50M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over VTGN on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
VTGN Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +13% | +4.9M shares |
| 1 year | +35% | +11M shares |
| 3 years | +500% | +35.8M shares |
| 5 years | +783% | +38.1M shares |
| Available history | +2925% | +41.6M shares |
VTGN has 43M diluted shares, up 35% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2025 | — |
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
VTGN Net Leverage
VTGN's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
VTGN Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 30.7 | Neutral |
| Stochastic | 1.6 | Oversold |
VTGN's weekly RSI is 31 (neutral) and its Stochastic is 2 (oversold).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
VTGN PE vs Healthcare Sector
VTGN has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
VTGN Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.21 | 14% below |
| 20 week MA | $0.23 | 22% below |
| 50 week MA | $0.61 | 70% below |
| 100 week MA | $1.79 | 90% below |
| 200 week MA | $2.90 | 94% below |
VTGN is in a downtrend: it's below all five of its weekly moving averages, and 94% below its 200-week average.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS has the edge over VTGN on returns for 2026, with the stronger performance.
VTGN Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $21.0 | $41.7 | +99% |
| 2021 | $41.7 | $60.9 | +46% |
| 2022 | $60.9 | $3.00 | -95% |
| 2023 | $3.00 | $5.14 | +71% |
| 2024 | $5.14 | $2.57 | -50% |
| 2025 | $2.57 | $0.73 | -72% |
| 2026 YTD | $0.73 | $0.18 | -75% |
VTGN has finished lower in three of the last six years. It's down 75% so far in 2026.